Alector, Inc. (ALEC)
ALECNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$2.43
+0.1100 (+4.74%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $366.24m
- P/E
- 6.9
- EPS, last 4 quarters
- $0.3500
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.09 to $2.76
- Average volume
- 3.67m
- Previous close
- $2.32
Analysts
7 coveringHold2 buy, 3 hold, 2 sell
Targets a year out average $3.90, +60.5% from here
Earnings
next estimate $0.1400Next report
Dec 2025
+12.8%
Mar 2026
+40.0%
Jun 2026
+12.5%
Sep 2026
+582.6%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $3.26m | $6.24m | $1.05m | $3.32m |
| Gross profit | $3.26m | $6.24m | $1.05m | $3.32m |
| Operating income | -$37.61m | -$39.57m | -$24.92m | -$24.39m |
| Net income | -$34.67m | -$37.27m | -$22.93m | -$22.99m |
Last four quarters: revenue $13.86m, margin -850.1%, free cash flow –
News
8 latest- Alector Consensus Price Target Increased by 15.38% to $4.59Fintel · Nov 2, 2026
- Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to DeclineZacks · Oct 30, 2026
- Will Alector (ALEC) Report Negative Q3 Earnings? What You Should KnowZacks · Oct 29, 2026
- Alector Consensus Price Target Increased by 25.81% to $3.98Fintel · Oct 23, 2026
- Alector Maps Brain-Delivery Pipeline for Alzheimer’s, Parkinson’s TherapiesMarketBeat · Oct 13, 2026
- Alector Signs Global License Deal With Genentech For AL050 RTTNews · Oct 5, 2026
- Novartis Halts Development Of VHB937 After ASTRALS Phase 2 Trial Fails To Meet Endpoint RTTNews · Sep 17, 2026
- Rani Therapeutics Appoints Nicholas Maestas CFO Following Sanford Departure RTTNews · Jun 30, 2026
The company
Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector's product candidates seek to treat a range of indications, such as Alzheimer's disease and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- alector.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.